| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Texasin selectively targets human leukocyte 5-lipoxygenase (5-LOX). 5-Lipoxygenase is a key enzyme in the biosynthesis of leukotrienes, which are potent inflammatory mediators derived from arachidonic acid. By inhibiting 5-LOX, Texasin reduces the production of pro-inflammatory leukotrienes and cytokines. This enzyme is also involved in the metabolism of arachidonic acid and is a well-established target for anti-inflammatory drug development. The compound may also inhibit cyclooxygenase (COX).
|
|---|---|
| ln Vitro |
Texasin demonstrates selective inhibition of human leukocyte 5-lipoxygenase in vitro. The compound inhibits the production of pro-inflammatory cytokines that contribute to tissue damage. It also exhibits antioxidative properties. The compound's ability to modulate immune cell activity suggests it can reduce excessive inflammation without broadly suppressing the immune system. Detailed IC50 values, specific assay conditions, and comparative data against other lipoxygenase isoforms are not extensively provided in the available literature.
|
| ln Vivo |
In vivo activity of Texasin is not extensively detailed in the available literature. Based on its mechanism as a 5-lipoxygenase inhibitor, the compound would be expected to reduce leukotriene-mediated inflammation in vivo. Animal models of inflammatory diseases such as rheumatoid arthritis, lupus, and multiple sclerosis could be used to evaluate its therapeutic potential. The compound's aim to selectively target immune regulation pathways suggests potential for reducing inflammation in autoimmune and inflammatory conditions. Specific in vivo efficacy data, doses, and routes of administration are not provided.
|
| Enzyme Assay |
In vitro enzyme assays for Texasin involve measuring 5-lipoxygenase activity in the presence of varying concentrations of the compound. Human leukocyte 5-lipoxygenase enzyme preparations are incubated with arachidonic acid substrate and Texasin (typically 0.01-100 μM) in appropriate buffer containing calcium and ATP. The reaction is initiated by addition of substrate and terminated by acidification. Product formation (5-HETE or leukotrienes) is quantified by HPLC or ELISA. IC50 values are calculated from concentration-response curves. Control experiments with known 5-LOX inhibitors (e.g., zileuton) are included for comparison. COX-1 and COX-2 inhibitory activity can also be assessed using similar protocols.
|
| Cell Assay |
For in vitro cell-based assays, human leukocytes or immune cells (e.g., macrophages, monocytes) are cultured and stimulated with appropriate inflammatory stimuli (e.g., lipopolysaccharide, calcium ionophore) to induce 5-lipoxygenase activity and leukotriene production. Cells are pre-incubated with Texasin at various concentrations (typically 0.1-100 μM) for 1-4 hours prior to stimulation. Leukotriene B4 (LTB4) and other inflammatory cytokines are measured in cell culture supernatants by ELISA or LC-MS. Cell viability is assessed using MTT or similar assays to ensure observed effects are not due to cytotoxicity. Anti-inflammatory activity is evaluated by measuring cytokine levels (TNF-α, IL-1β, IL-6).
|
| Animal Protocol |
In vivo animal models for Texasin could include rodent models of inflammation such as carrageenan-induced paw edema, zymosan-induced peritonitis, or collagen-induced arthritis. The compound would be administered orally or intraperitoneally at doses determined from pilot studies. Inflammatory markers (cytokines, leukotrienes) would be measured in plasma or tissue homogenates. Clinical scores (paw swelling, joint inflammation) would be recorded in arthritis models. Histological examination of affected tissues would assess the extent of inflammation and tissue damage. Specific protocols using Texasin are not extensively documented in the available literature.
|
| ADME/Pharmacokinetics |
Texasin is a small molecule with a molecular weight of 284.26 and molecular formula C16H12O5. It should be stored as powder at -20°C for up to 3 years and in solvent at -80°C for up to 1 year. The compound's solubility and pharmacokinetic properties (absorption, distribution, metabolism, excretion, half-life) are not extensively characterized in the available literature. As a 5-lipoxygenase inhibitor, it would be expected to be orally bioavailable if formulated appropriately. Specific PK data from animal studies are not provided.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Texasin are not provided in the available literature. As a 5-lipoxygenase inhibitor, it would be expected to have a safety profile similar to other compounds in this class. The compound's selective targeting of immune regulation pathways aims to reduce excessive inflammation without broadly suppressing the immune system, potentially improving the safety profile compared to non-selective immunosuppressants. Standard toxicology assessments would be required for therapeutic development, including acute toxicity, repeated-dose toxicity, genotoxicity, and reproductive toxicity studies.
|
| References |
[1]. Isoflavonoids from Caragana changduensis and their nitric oxideinhibitory activities]. Zhongguo Zhong Yao Za Zhi. 2015 Aug;40(16):3220-3.
[2]. A new isoflavone glycoside from Baptisia australis. J Org Chem. 1968 Jan;33(1):462-4. |
| Additional Infomation |
Texasin is a 4'-methoxyisoflavone compound. It has been reported that red clover and Australian wild indigo contain texasin, and relevant data are available for reference.
Texasin is a selective inhibitor of human leukocyte 5-lipoxygenase, also known as IR-2. It modulates immune cell activity and inhibits the production of pro-inflammatory cytokines involved in diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. The compound aims to selectively target specific immune regulation pathways, reducing excessive inflammation without broadly suppressing the immune system. Texasin also exhibits antioxidative properties and may inhibit cyclooxygenase. No approved therapeutic status is reported. Further research is needed to fully characterize its in vivo efficacy, pharmacokinetics, and safety profile. |
| Molecular Formula |
C16H12O5
|
|---|---|
| Molecular Weight |
284.263484954834
|
| Exact Mass |
284.068
|
| CAS # |
897-46-1
|
| PubChem CID |
5281812
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.42g/cm3
|
| Boiling Point |
546ºC at 760 mmHg
|
| Flash Point |
209.5ºC
|
| Index of Refraction |
1.668
|
| LogP |
2.879
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1OC2=CC(O)=C(O)C=C2C(=O)C=1C1=CC=C(OC)C=C1
|
| InChi Key |
GCWOYVFHJDNKIN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O5/c1-20-10-4-2-9(3-5-10)12-8-21-15-7-14(18)13(17)6-11(15)16(12)19/h2-8,17-18H,1H3
|
| Chemical Name |
6,7-Dihydroxy-3-(4-methoxyphenyl)-4-benzopyrone
|
| Synonyms |
IR-2 IR 2 IR2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~439.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | |
| 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | |
| 10 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA